GC Wellbeing finds placenta injection relieves COVIID-19 symptoms through animal testing

SEOUL -- Laennec, a placenta injection, was found to have relieved symptoms of COVID-19 in an animal experiment by GC Wellbeing, the health therapy wing of South Korean pharmaceutical company GC Pharma. Laennec made from human placenta extract is a medicine used to improve liver function in chronic liver diseases.

GC Wellbeing said on Wednesday that the company has carried out joint research with a team from Chungbuk National University's College of Medicine to find that a COVID-19-infected ferret showed statically significant results when Laennec was applied through an intravenous injection.

After the placenta injection was applied for four days, the ferret's fever was reduced, GC Wellbeing said, adding that from the sixth day, the amount of COVID-19 virus in the ferret's nasal cleaning fluid has statically and significantly decreased.

"If the anti-viral action in the body is proven, it is expected to be effective against COVID-19," a GC Wellbeing official was quoted as saying. The official said that Laennec has anti-inflammatory effects, pain suppression and immune enhancement against inflammatory damage to various cells that occur during virus infections.